Navigation Links
TESARO and Virginia G. Piper Cancer Center announce first patient in clinical trial of TSR-011
Date:11/1/2012

WALTHAM, Mass. Nov. 1, 2012 TESARO, Inc. (Nasdaq: TSRO) announced today that the first clinical trial of its proprietary Anaplastic Lymphoma Kinase (ALK) inhibitor, TSR-011, has commenced with the dosing of the first patient at the Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare, a partnership between Scottsdale Healthcare and the Translational Genomics Research Institute (TGen).

TSR-011 is an orally available ALK inhibitor (targeted anti-cancer agent) that will be studied in patients, including non-small cell lung cancer (NSCLC) patients, with ALK+ tumors. TESARO plans to expand the Phase 1/2 clinical trial of TSR-011 to multiple clinical trial sites in the U.S. and Europe.

"TSR-011 has the profile of a promising targeted anti-cancer agent and we are enthusiastic about the opportunity to investigate its potential in patients," said Dr. Glen Weiss, Director of Thoracic Oncology at the Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare and Clinical Associate Professor at TGen.

Following identification of the maximum tolerated dose of TSR-011 in patients with advanced cancer during the dose escalation phase of the trial, TESARO plans to evaluate TSR-011 in three parallel cohorts of patients in the phase 2 portion: those with ALK+ NSCLC who have not been previously treated with ALK inhibitors, those with NSCLC who have progressed during treatment with other ALK inhibitors, and those with other tumor types expressing ALK.

"We are very pleased to have progressed TSR-011 into a human clinical trial and look forward to identifying a dose that may be utilized in the expansion phase of the study which will assess both the safety and efficacy of the compound," said Mary Lynne Hedley, Ph.D., TESARO's President and Chief Scientific Officer. "ALK is a key driver of subsets of NSCLC, and may also contribute to the growth of neuroblastoma, lymphoma and other cancers. In order to maximize the commercial potential of TSR-011, we plan to study TSR-011 in multiple treatment and tumor settings."

About Anaplastic Lymphoma Kinase and Non-Small Cell Lung Cancer

ALK gene fusions that result in constitutive activation of ALK are associated with sub-sets of certain cancers including non-small cell lung cancer (NSCLC). Abnormal ALK proteins are also associated with sub-populations of other cancers including lymphoma and neuroblastoma. ALK is generally not expressed in normal adult tissue and therefore represents a promising molecular target for the development of a cancer therapeutic.

According to the American Cancer Society, over 1.6 million new lung cancer cases are identified worldwide annually, of which over 200,000 of these new lung cancer cases are in the United States. Lung cancer is the leading cause of cancer death in men and the second leading cause of cancer death in women. Lung cancer is typically divided into two groups based upon the histologic appearance of the tumor cellssmall cell and non-small cell lung cancer, each of which is treated with distinct chemotherapeutic approaches. According to the American Cancer Society, NSCLC accounts for approximately 85% of lung cancer cases, with approximately 75% of these patients being diagnosed with metastatic or advanced disease. Despite the introduction of new therapies patients with locally advanced or metastatic NSCLC have five-year survival rates of just 24% and 4%, respectively, according to the Surveillance Epidemiology and End Results program of the National Cancer Institute. ALK is believed to be a key driver of tumor development in approximately 5% of all NSCLC patients.


'/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Related biology news :

1. Virginia Tech announces 2012 football helmet ratings; 2 more added to the 5-star mark
2. Biology professor secures grant to save West Virginias primary natural history collection
3. Virginia Tech and University of Tuscia lead team to unravel origin of devastating kiwifruit bacterium
4. Scientific meeting at Virginia Tech will make more than $2 million economic impact
5. Old deeds, witness trees offer glimpse of pre-settlement forest in West Virginia
6. Tortoise and the hare: New drug stops rushing cancer cells, slow and steady healthy cells unharmed
7. Embryonic development protein active in cancer growth
8. BRG1 mutations confer resistance to hormones in lung cancer
9. Genetic variation in East Asians found to explain resistance to cancer drugs
10. Beyond the microscope: Identifying specific cancers using molecular analysis
11. Marshall University study may lead to new treatments for prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2017)... , May 16, 2017  Veratad Technologies, LLC ( ... online age and identity verification solutions, announced today they ... Conference 2017, May 15 thru May 17, 2017, in ... and International Trade Center. Identity impacts ... and in today,s quickly evolving digital world, defining identity ...
(Date:4/18/2017)... , April 18, 2017  Socionext Inc., a global expert in ... media edge server, the M820, which features the company,s hybrid codec ... provided by Tera Probe, Inc., will be showcased during the upcoming ... NAB show at the Las Vegas Convention ... Click ...
(Date:4/11/2017)... Research and Markets has announced the addition of the ... ... to grow at a CAGR of 30.37% during the period 2017-2021. ... been prepared based on an in-depth market analysis with inputs from ... prospects over the coming years. The report also includes a discussion ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... CA, USA (PRWEB) , ... October 11, 2017 , ... ... to take place on 7th and 8th June 2018 in San Francisco, CA. The ... influencers as well as several distinguished CEOs, board directors and government officials from around ...
(Date:10/11/2017)... the Netherlands and LAGUNA HILLS, Calif. ... The Institute of Cancer Research, London ... use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify patients ... trial known as MUK nine . The University of ... trial, which is partly funded by Myeloma UK, and ICR ...
(Date:10/11/2017)... ... October 11, 2017 , ... Singh ... orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of ... SBT-100 is able to cross the cell membrane and bind intracellular STAT3 and ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... program has won a US2020 STEM Mentoring Award. Representatives of the FirstHand program ... in Volunteer Experience from US2020. , US2020’s mission is to change the trajectory ...
Breaking Biology Technology: